SGMO
Sangamo Therapeutics, Inc.NASDAQHealthcare$0.30-7.16%ClosedMarket Cap: $111.5M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
-6.59
P/S
2.62
EV/EBITDA
-0.92
DCF Value
$-1.12
FCF Yield
-94.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
64.0%
Operating Margin
-306.5%
Net Margin
-310.8%
ROE
-2983.2%
ROA
-205.8%
ROIC
-698.4%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $14.2M | 0.0% | $-38.2M | $-37.4M | $-0.11 | — |
| FY 2025 | $39.6M | 0.0% | $-121.2M | $-122.9M | $-0.44 | — |
| Q3 2025 | $581.0K | 100.0% | $-35.6M | $-34.9M | $-0.11 | — |
| Q2 2025 | $18.3M | 100.0% | $-17.9M | $-20.0M | $-0.08 | — |
| Q1 2025 | $6.4M | 100.0% | $-29.6M | $-30.6M | $-0.14 | — |
| Q4 2024 | $7.6M | 100.0% | $-26.0M | $-23.4M | $-0.11 | — |
| FY 2024 | $57.8M | 100.0% | $-104.0M | $-97.9M | $-0.49 | — |
| Q3 2024 | $49.4M | 100.0% | $10.6M | $10.7M | $0.04 | — |
| Q2 2024 | $356.0K | 100.0% | $-37.1M | $-36.1M | $-0.18 | — |
| Q1 2024 | $481.0K | 100.0% | $-51.5M | $-49.1M | $-0.27 | — |
| Q4 2023 | $2.0M | 100.0% | $-62.1M | $-60.3M | $-0.34 | — |
| FY 2023 | $176.2M | 100.0% | $-274.0M | $-257.8M | $-1.48 | — |